03.11.2022 - - Reported positive preclinical data for its next-generation KRASG12C GTP/GDP dual inhibitor development candidate, BBO-8520, and for its novel PI3Kα:RAS breaker mechanism in late lead optimization - Reported positive updated 12-month Phase 2 data .
EQS-News: Fortress Biotech, Inc. Fortress Bio’s Portfolio Of Marketed Drugs Could Soon See Three Additions 06.10.2022 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Fortress Biotech Inc. (NASDAQ: FBIO) is a biopharmaceutical company focused on developing .
Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer - read this article along with other careers information, tips and advice on BioSpace